<SEC-DOCUMENT>0001564590-23-002247.txt : 20230223
<SEC-HEADER>0001564590-23-002247.hdr.sgml : 20230223
<ACCEPTANCE-DATETIME>20230222200623
ACCESSION NUMBER:		0001564590-23-002247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230221
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230223
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		23655546

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>staa-8k_20230221.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-02-23T00:55:40.8122005+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : deb5d3bb718046e4a3e35304f41869b7 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:staa="http://www.staar.com/20230221" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
staa-8k_20230221.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000718937_20230221_20230221">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000718937_20230221_20230221">0000718937</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="staa-20230221.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000718937_20230221_20230221">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2023-02-21</xbrli:startDate>
					<xbrli:endDate>2023-02-21</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;margin-left:37.49%;margin-right:34.51%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<span style="letter-spacing:-0.05pt;">N</span>IT<span style="letter-spacing:-0.05pt;">E</span>D S<span style="letter-spacing:0.05pt;">T</span>A<span style="letter-spacing:0.05pt;">T</span>ES</p>
<p style="text-align:center;margin-bottom:0pt;line-height:20pt;margin-top:0pt;margin-left:14.71%;margin-right:11.75%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S<span style="letter-spacing:-0.05pt;">E</span>C<span style="letter-spacing:-0.05pt;">U</span><span style="letter-spacing:0.05pt;">R</span>IT<span style="letter-spacing:-0.1pt;">I</span><span style="letter-spacing:0.1pt;">E</span>S A<span style="letter-spacing:-0.05pt;">N</span>D E<span style="letter-spacing:0.2pt;">X</span>CHA<span style="letter-spacing:-0.05pt;">N</span>GE<span style="letter-spacing:0.05pt;"> </span>CO<span style="letter-spacing:-0.05pt;">M</span>MISSION</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:37.46%;margin-right:35.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WAS<span style="letter-spacing:0.05pt;">H</span>IN<span style="letter-spacing:-0.1pt;">G</span>TON, DC<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">2</span>0549</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000718937_20230221_20230221">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:33.24%;margin-right:30.41%;text-indent:0.01%;font-weight:bold;font-size:12pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">P<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:0.05pt;">u</span>a<span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>tion<span style="letter-spacing:0.1pt;"> </span>13 or<span style="letter-spacing:-0.05pt;"> </span>15(d) of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">ec</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ities Excha<span style="letter-spacing:0.05pt;">n</span>ge<span style="letter-spacing:-0.05pt;"> </span>A<span style="letter-spacing:0.05pt;">c</span>t of<span style="letter-spacing:0.05pt;"> </span>1934</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:17.08%;margin-right:14.74%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Da<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>t<span style="letter-spacing:0.05pt;"> </span>(<span style="letter-spacing:-0.05pt;">D</span>a<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">r</span>l<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">e</span>st <span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.1pt;">v</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.1pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:0.05pt;">r</span>t<span style="letter-spacing:-0.1pt;">e</span><span style="letter-spacing:0.05pt;">d)</span>: <span style="letter-spacing:-0.7pt;"> </span><ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000718937_20230221_20230221" format="ixt:datemonthdayyearen">February 21, 2023</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:7pt;text-indent:0%;font-size:7.5pt;">&#160;</p>

<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.41%;margin-right:28.17%;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000718937_20230221_20230221">STAAR Surgical Co</ix:nonNumeric>mpany<span style="letter-spacing:0.05pt;color:#000000;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.35%;margin-right:28.17%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-style:normal;text-transform:none;font-variant: normal;">(<span style="letter-spacing:-0.05pt;">Ex</span>act<span style="letter-spacing:-0.25pt;"> </span>N<span style="letter-spacing:0.2pt;">a</span><span style="letter-spacing:-0.15pt;">m</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Re<span style="letter-spacing:0.1pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>trant<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">p</span>ecified<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">i</span>n<span style="letter-spacing:-0.1pt;"> </span>Charter)</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000718937_20230221_20230221">0-11634</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000718937_20230221_20230221">95-3797439</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000718937_20230221_20230221">25651 Atlantic Ocean Drive</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000718937_20230221_20230221">Lake Forest</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000718937_20230221_20230221">92630</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: <span style="text-decoration:underline;font-family:Times New Roman;"><ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000718937_20230221_20230221">626</ix:nonNumeric></span>-<ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000718937_20230221_20230221">303-7902</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0.93%;margin-right:1.87%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Che<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he a<span style="letter-spacing:0.05pt;">ppropr</span>iate<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">bo</span>x<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.1pt;">l</span><span style="letter-spacing:0.15pt;">o</span>w<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:0.1pt;"> </span>the F<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:0.15pt;">r</span>m<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">8</span><span style="letter-spacing:-0.1pt;">-</span>K <span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>ten<span style="letter-spacing:0.05pt;">d</span>ed<span style="letter-spacing:-0.25pt;"> </span>to s<span style="letter-spacing:0.1pt;">i</span>mult<span style="letter-spacing:0.1pt;">a</span>ne<span style="letter-spacing:0.05pt;">o</span>u<span style="letter-spacing:0.1pt;">sl</span>y<span style="letter-spacing:-0.65pt;"> </span>sati<span style="letter-spacing:0.1pt;">s</span><span style="letter-spacing:0.05pt;">f</span>y<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">ob</span>l<span style="letter-spacing:0.1pt;">i</span>gati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>the <span style="letter-spacing:0.15pt;">r</span>egistr<span style="letter-spacing:0.15pt;">a</span>nt un<span style="letter-spacing:0.05pt;">d</span>er<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he <span style="letter-spacing:-0.1pt;">f</span><span style="letter-spacing:0.05pt;">o</span>ll<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">pro</span>visi<span style="letter-spacing:0.15pt;">o</span>ns<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.25pt;">(</span><span style="font-style:italic;">s</span><span style="font-style:italic;">ee</span><span style="font-style:italic;"> </span>G<span style="letter-spacing:0.15pt;">e</span>ne<span style="letter-spacing:0.05pt;">r</span>al<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">I</span>n<span style="letter-spacing:0.1pt;">s</span>tructi<span style="letter-spacing:0.15pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>.<span style="letter-spacing:0.05pt;">2</span>.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">b</span>el<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.25pt;">w</span><span style="letter-spacing:0.05pt;">)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.04%;">
<tr>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000718937_20230221_20230221">Common</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000718937_20230221_20230221">STAA</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000718937_20230221_20230221">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;line-height:11pt;margin-top:0pt;margin-left:0.93%;margin-right:0.56%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> m</span>a<span style="letter-spacing:0.15pt;">r</span>k<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">e</span>ther<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>tr<span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>pany<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>defi<span style="letter-spacing:-0.05pt;">n</span>ed<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>R<span style="letter-spacing:-0.05pt;">u</span>le<span style="letter-spacing:-0.2pt;"> </span>405<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>1<span style="letter-spacing:-1.8pt;"> </span>933 (17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;230<span style="letter-spacing:-0.1pt;">.</span>405)<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> Ru</span>le<span style="letter-spacing:-0.2pt;"> </span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.25pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">E</span><span style="letter-spacing:-0.05pt;">x</span><span style="letter-spacing:0.15pt;">c</span>han<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>1934<span style="letter-spacing:-0.15pt;"> </span>(17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;240<span style="letter-spacing:-0.1pt;">.</span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.3pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2).</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.94%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E<span style="letter-spacing:-0.2pt;">m</span>e<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.05pt;">r</span>o<span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span><span style="letter-spacing:0.05pt;">p</span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:1.3pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.3pt;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000718937_20230221_20230221" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:5pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span>th<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.2pt;">y</span>,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ark<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>istra<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">h</span>as<span style="letter-spacing:-0.15pt;"> </span>elected<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">n</span>ot<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">us</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>t<span style="letter-spacing:0.1pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>ded<span style="letter-spacing:-0.25pt;"> </span>tra<span style="letter-spacing:-0.05pt;">ns</span>i<span style="letter-spacing:0.1pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>period<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>or co<span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.1pt;">l</span><span style="letter-spacing:-0.05pt;">y</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span>th<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">a</span>ny<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">e</span>w<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">s</span>ed<span style="letter-spacing:-0.1pt;"> f</span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>cial<span style="letter-spacing:-0.3pt;"> </span>accou<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:0.1pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>da<span style="letter-spacing:0.4pt;">r</span>ds<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:-0.05pt;">v</span>ided<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;">su</span>a<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">S</span>ection<span style="letter-spacing:-0.35pt;"> </span>13(a)<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>E<span style="letter-spacing:-0.05pt;">x</span>c<span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct.<span style="letter-spacing:1.8pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.8pt;">&#9744;</span></p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01 Regulation FD Disclosure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 21, 2023, the Company held a conference call to discuss the financial results for the quarter and fiscal year ended December 30, 2022.&#160;&#160;A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.75pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:2.35pt;"></td>
<td style="width:469.75pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exhibit No.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="staa-ex991_24.htm"><span style="text-decoration:underline;">Transcript of conference call of the Company held on February 21, 2023</span></a><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;"><span style="margin-left:36pt;"></span>&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.5pt;;">
<tr>
<td style="width:85.25pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:471.9pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.8pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:18.2pt;"></td>
<td style="width:465.3pt;"></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAAR Surgical Company&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 22, 2023</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">/s/ Tom Frinzi</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas G. Frinzi</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>staa-ex991_24.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
staa-ex991_24.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#1900FF">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:18pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#001EFF;font-size:14pt;">CORPORATE PARTICIPANTS</font><font style="font-weight:bold;color:#001EFF;font-size:14pt;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-style:italic;">STAAR Surgical Company - VP of Investor, Media </font><font style="font-style:italic;">Relations &amp; Corporate Development</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-style:italic;"></font><font style="font-weight:bold;color:#001EFF;font-size:14pt;">CONFERENCE CALL PARTICIPANTS</font><font style="font-weight:bold;color:#001EFF;font-size:14pt;"></font><font style="font-weight:bold;">Anthony Charles </font><font style="font-weight:bold;">Petrone</font><font style="font-weight:bold;"> </font><font style="font-style:italic;">Mizuho Securities USA LLC, Research Division - MD &amp;</font><font style="font-style:italic;"> Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst</font><font style="font-style:italic;"></font><font style="font-weight:bold;">David Joshua Saxon </font><font style="font-style:italic;">Needham &amp; Company, LLC, Research Division - Senior Analyst</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Malgorzata Maria </font><font style="font-weight:bold;">Kaczor</font><font style="font-weight:bold;"> Andrew </font><font style="font-style:italic;">William Blair &amp; Company L.L.C., Research Division - Research Analyst </font><font style="font-style:italic;">&amp; Partner</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Ryan Benjamin Zimmerman </font><font style="font-style:italic;">BTIG, LLC, Research Division - MD &amp; Medical Technology Analyst</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Thomas M. Stephan </font><font style="font-style:italic;">Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font><font style="font-style:italic;"></font><font style="font-weight:bold;">Unidentified </font><font style="font-weight:bold;">Analyst </font><font style="font-style:italic;"> -</font><font style="font-style:italic;"> </font><font style="font-style:italic;"></font><font style="font-weight:bold;">Zachary Ross Weiner </font><font style="font-style:italic;">Jefferies LLC, Research </font><font style="font-style:italic;">Division - Equity Associate</font><font style="font-style:italic;"></font><font style="font-weight:bold;color:#001EFF;font-size:14pt;">PRESENTATION</font><font style="font-weight:bold;color:#001EFF;font-size:14pt;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call. (Operator Instructions) This call is being re</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corded today, Tuesday, February 21, 2023.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, I would like to turn the conference over to Mr. Brian Moore, Vice President, Investor, Media Relations and Corporate Development for STAAR Surgical.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, operator. Good afternoon, everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> discuss the company's financial results for the fourth quarter and fiscal year ended December 30, 2022. On the call today are Tom Frinzi, Chair of the Board, President and CEO; and Patrick Williams, Chief Financial Officer. The press release of our fourth</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> quarter results was issued just after 4:00 p.m. Eastern Time and is now available on STAAR's website at www.staar.com.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statem</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and prospects. These statements are based on judgment and</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks and uncertainties associa</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted with the forward-looking statements made in this conference call </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and webcast are described in the safe harbor statement in today's press release as well as STAAR's public periodic filings with the SEC. Except as required by law, STAAR assumes no obliga</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales i</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n constant currency.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> today's press release. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit themselves to 2 initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperat</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion with this process.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And with that, I would now like to turn the call over to Tom Frinzi. Tom?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Than</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ks, Brian, and good afternoon, everyone, and thank you for joining us. I will begin with an overview of our results for the fourth quarter and fiscal year before turning my commentary to my first 50 days as CEO and our priorities for 2023. Patrick will the</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n provide additional details on our financial performance and outlook for 2023. We will then open the call to questions.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I am pleased to report that once again in fiscal 2022, STAAR achieved a multi-quarter track record of market-leading top line growth. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICL sales grew 27% year-over-year, and in constant currency, 32%. ICL units grew 33%. We continue to maintain our position as one of the few high-growth publicly traded medical device companies with positive GAAP earnings while also increasing our investme</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nts in key areas to continue future growth. STAAR is also a company that generates strong operating cash flow. In fiscal 2022, we increased cash on our balance sheet by over $25 million through internal generated funds, ending the year with over $225 milli</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on of cash and investments.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth quarter sales results also increased. ICL unit growth was up 20% year-over-year, and ICL sales were up 21% in constant currency year-over-year. In the fourth quarter, year-over-year ICL sales growth was led by our APAC a</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd North America regions while EMEA sales were up slightly on a sequential basis. Year-over-year ICL unit growth by country in the fourth quarter was as follows: in China, units up 18%; Japan, units up 33%; India, units up 19%; and the U.S., units up 109%.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I know top of mind for many of you is the state of the market in China and our progress in the U.S. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> let's begin with China. During the fourth quarter, refractive procedures, including EVO in China were impacted by COVID. First, beginning with the chan</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ge in consumer behavior that STAAR called out on the November 2, 2022 earnings call. Later, protests and the lifting of the country's COVID Zero policy follow. Then a subsequent rise in COVID infections further impacted the level of refractive procedures i</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n the fourth quarter. Against </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these operating backdrop</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we are proud to deliver 18% ICL unit growth in China for the fourth quarter of 2022.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through the first 7 weeks of the first quarter of 2023, we see encouraging signs of market stabilization, restorat</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion and resilience. Weekly sales results and end market procedural volumes in China are in line with our expectations. So while we consider it premature to declare that the China market has fully normalized, we do have greater confidence today that the mar</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ket in China will further normalize as we approach the peak summer implant season for ICL procedures. The strong EVO commitments from our larger customers in China, the largest refractive market in the world and many of the 1,200-plus surgeons in China tha</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t implant our lenses bolsters our confidence at this time that we can meet our sales outlook for the full year fiscal 2023.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to the U.S. ICL unit growth exceeded the outlook we previously provided, up 55% year-over-year in fiscal 2022 and up 109% y</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ear-over-year in the fourth quarter. We exited the fourth quarter with more than 600 surgeons certified to implant EVO lenses in the U.S. While we continue to train and certify surgeons in the U.S., our focus for 2023 is increasing surgeon comfort, confide</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nce and commitment to EVO by surrounding our surgeon customers with sales, clinical and marketing support as they work to add EVO to their practices and/or transform their practices for more lens-based refractive standard.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From a marketing perspective, we</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are receiving positive feedback from U.S. surgeons that our marketing is raising EVO brand awareness and consumer desirability. The data also illustrates that our marketing is having a positive impact on sales. As an example, in our targeted cities during</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the fourth quarter of 2022, we achieved greater sales growth where we activated advertising compared to key cities where we did not advertise. During the fourth quarter, when we launched the Joe Jonas advertising campaign, we saw sales growth almost doubl</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e in targeted cities where we advertise as compared to key cities where we did not advertise. Activity on our Doctor Finder has also increased.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Doctor Finder visits in the U.S. were up approximately 600% year-over-year in the fourth quarter. We are also s</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">urrounding our U.S. surgeons with clinical and sales support to demonstrate the medical and economic promise of EVO no matter the surgical setting. As many of you already know, the predominant procedure in our industry, laser vision correction has been exp</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eriencing challenges. At the same time, increased compression and reimbursement for cataract IOLs and other ophthalmic procedures as more and more doctors showing interest in EVO. The refractive surgery industry has been looking for the next big technology</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We believe it is EVO.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">My meetings in recent weeks with surgeon customers confirm the growth opportunity for EVO in the U.S. In one meeting, I met with an individual surgeon, increasing his commitment to EVO from 100 lenses per year to 500 plus. In anoth</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er instance, I met with a laser vision correction chain that is increasing its commitment to EVO from 500 lenses to 2,000-plus annual lenses in 2023. I'm also encouraged by EVO's increasing presence in clinical papers on podiums and industry panels.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Next </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">week, as part of the American-European Congress of Ophthalmic Surgeons, AECOS, in their Winter Symposium, STAAR's Chief Medical Officer, Dr. Scott Barnes, will participate in a panel with other key opinion leaders and speak to the benefits of EVO. The pane</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l is titled life after LASIK. As I reflect on my first 50 days as CEO, I have been able to more closely assess STAAR's business, people and overall </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">strategy. Our international business is well established and will continue to show growth. We are now EVO-fo</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cused on realizing the tremendous potential that the U.S. market represents. As a direct result of STAAR's prudent fiscal management over the last several years, we are now in a position of financial strength and stability.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to take full advantage </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of STAAR's financial strength to build the U.S. market, particularly given the refractive surgery market dynamics I described earlier. To accelerate consumer awareness, surgeon confidence in EVO adoption in the U.S., STAAR will move forward with even great</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er intent and purpose. In 2023, this will include investments in additional sales, practice development and clinical applications personnel as well as doubling our spend on EVO digital marketing campaigns. It's time. It's lens-based refractive surgeries ti</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">me, which means it's EVO's time.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patrick?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Tom, and good afternoon, everyone. Total net sales for Q4 2022 were</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $64 million, consistent with our January 9 pre-announcement as compared to net sales of $59 million in Q4 2021. The $5 million year-over-year increase in Q4 2022 net sales is attributable to a 15% or $8.1 million increase in ICL sales, partially offset by</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a $3.1 million decline in other products, which primarily consists of cataract IOLs. The company announced on November 2, 2022, that we will no longer support our noncore lower-margin cataract IOL business after 2023.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ICL sales represented 96% of total c</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompany net sales in Q4 2022. U.S. sales normalized for allowance for sales reserves were $4.5 million in Q4 2022, up 94% compared to Q4 2021 sales of $2.3 million. EVO was approved on March 25, 2022. Therefore, the year-ago period includes both </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Visian</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ICL </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and EVO ICL sales. We have posted a U.S. ICL sales supplement to our investor website under latest quarterly results. For Q4 2022, reported net sales included a $3.8 million negative impact from changes in constant currency, primarily the yen in Europe and</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the impact of the transient headwinds in China that Tom discussed earlier.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For fiscal 2022 reported net sales of $284 million included a $12.9 million negative impact for changes in constant currency, as outlined in the constant currency table in today's</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> earnings release. Our outlook for fiscal 2023 net sales is for ICL sales of approximately $340 million, representing 26% growth over fiscal 2022 ICL sales of approximately $270 million. We anticipate the calendarization of sales in fiscal 2023 will be wei</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ghted towards the second half of the year as transient headwinds subside. As a reminder, Q1 and Q4 has historically represented our seasonally lowest quarters. We expect Q1 2023 net sales will be up sequentially from Q4 2022 and in the range of $65 million</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to $67 million. U.S. sales in the first quarter are expected to be approximately $5 million, which represents approximately 100% year-over-year sales growth.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning back to Q4. Gross profit for Q4 2022 was $49.8 million or 77.7% of net sales as compared</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to gross profit of $45 million or 76.3% of net sales for Q4 2021 and $60.5 million or 79.5% of net sales for </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q3 2022. The </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140 basis</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> point year-over-year increase in gross margin is due mainly to product and geographic mix, partially offset by increased pe</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">riod costs associated with manufacturing projects. The sequential decrease in gross margin of 180 basis points from Q3 2022 is primarily due to product and geographic mix. For fiscal 2023, we expect gross margin will be approximately 80% for the full year </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and each quarter.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moving down the income statement. Total operating expenses for Q4 2022 were up 30% year-over-year to $48.8 million as compared to $37.6 million in Q4 2021 and $46.8 million for Q3 2022. Taking a closer look at the components of operating</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expenses, G&amp;A expense for Q4 '22 was $14.8 million compared to $11.5 million for Q4 2021 and $14 million for Q3 2022. The year-over-year increase in G&amp;A is due to increased compensation-related expenses, facilities costs and outside services. The sequenti</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al increase in G&amp;A is due to higher facility costs associated with our expanding corporate and manufacturing operations.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For fiscal 2023, we expect G&amp;A expense will be approximately 18% of net sales for the full year. For Q1 2023, we expect G&amp;A expense wi</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll be approximately $13 million and increase slightly for each subsequent quarter. Selling and marketing expense was $24.2 million for Q4 2022 compared to $17.1 million for Q4 2021 and $23.1 million for Q3 2022. The increase in selling and marketing expens</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e from the prior year is due to increased advertising and promotional activities, trade shows and sales meetings, travel expenses and compensation-related expenses.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sequential increase in selling and marketing expense from Q3 2022 is due to increased </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing, promotion and advertising expenses, partially offset by decreased trade shows and sales meetings. For fiscal 2023, we expect selling and marketing expenses will be approximately 38% of net sales as we make the important investments in EVO ICL pa</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tient awareness and our sales organization that Tom discussed earlier.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of calendarization, we expect selling and marketing expense will be approximately $30 million for Q1 2023 and $33 million each quarter thereafter. Research and development exp</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ense was $9.8 million in Q4 2022 compared to $9.1 million for Q4 2021 and $9.6 million for Q3 2022. The year-over-year and sequential increase in R&amp;D is due to increased expenses associated with our U.S. post-approval studies. For fiscal 2023, we expect R&amp;</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D expense will be approximately 13% for the full year, which is approximately $11 million each quarter. Operating income in Q4 2022 was $1 million or 1.5% of net sales as compared to $7.4 million or 12.5% of net sales for Q4 2021.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating income for fis</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cal 2022 was $43.8 million or 15.4% of net sales as compared to $33.3 million or 14.5% of net sales for fiscal 2021. We expect operating margin for fiscal 2023 will be approximately 12%. For Q4 2022, net income was $5.9 million or $0.12 per diluted share c</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompared to net income of $4.9 million or $0.10 per diluted share for Q4 2021. On a non-GAAP basis, adjusted net income for Q4 '22 was $6.8 million or $0.14 per diluted share compared to adjusted net income of $9.5 million or $0.19 per diluted share for Q4 </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021. A table reconciling the GAAP information to the non-GAAP information is included in today's financial release. For fiscal 2023, we expect our effective tax rate will be </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately 25% to 30%, subject to no significant change in our valuation allow</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ance.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning now to our balance sheet. Our cash, cash equivalents and both short-term and long-term investments available for sale totaled $225.5 million as of December 30, 2022, as compared to $199.7 million at December 31, 2021. In fiscal 2022, we gene</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rated $35.7 million in cash from operations and invested $18.1 million in property and equipment. For fiscal 2023, we expect to invest approximately $26 million in property and equipment, which includes approximately $2 million of carryover capital expendi</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tures that were planned for fiscal 2022. Our strategic investments in property and equipment are primarily to support manufacturing capacity expansion and a strong trajectory of sales growth.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This concludes our prepared remarks. Operator, we are now ready</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to take questions.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;color:#001EFF;font-size:14pt;">QUESTIONS AND ANSWERS</font><font style="font-weight:bold;color:#001EFF;font-size:14pt;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absolutely. (Operator Instructions) Our first question comes from the line of Margaret </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kaczor</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with William Blair.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Malgorzata Maria </font><font style="font-weight:bold;">Kaczor</font><font style="font-weight:bold;"> Andrew </font><font style="font-weight:bold;font-style:italic;">William Blair &amp; Company L.L.C., Research Division - Research Analyst &amp; Partner</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. I wanted to start maybe with the guidance for the year an</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d whether you guys can give us a more detailed sense, I guess, on a geographic unit growth basis, it's being implied and kind of how the inputs may have changed versus the guidance in January? And I asked because it sounds like the guidance was directional</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly, at least come to directionally more bullish on China as you expected maybe headwinds in Q2 previously, and you're seeing things ease now, and then similarly on the U.S. with the $5 million to start the year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure, Margaret, this is Tom. Thank you for the question. And as it relates to China, I think -- I don't know if we would say bullish is the right </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">word, but we certainly are confident. Our local team certainly has expressed confidence in terms of what's happening at the street level with China. We're not seeing COVID testing. There are no travel restrictions. We're seeing more normal refractive proce</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dures being done at the eye clinic. So together with the confidence of our local team, I think we remain confident that we can deliver on the China's projections for this year as previously stated.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. Margaret, I think in relation to your question on the composition, nothing has materially changed, right? We gave the guidance back on early January, the $340 million. We rec</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onfirm that today. You heard Tom's comments just now. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we're feeling good about where we're at and where the year is shaping up at this point. But the overall composition is nothing has materially changed when we gave the original guidance.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Malgorzata Maria </font><font style="font-weight:bold;">Kaczor</font><font style="font-weight:bold;"> Andrew </font><font style="font-weight:bold;font-style:italic;">William Blair &amp; Company L.L.C., Research Division - Research Analyst &amp; Partner</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Great. And then on the U.S. EVO launch, Tom, I appreciate your comm</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents and kind of the outlook there that was encouraging. But I'm curious if we could follow up a little bit on the practice development efforts that you spoke to launching. What kind of support are you going to provide? How broadly might this roll out as a</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> benefit, timing of impact and maybe any metrics if you trial this that you saw that, that made you want to kind of double down on it?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Com</font><font style="font-weight:bold;font-style:italic;">pany - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. Again, I would just say, given my experience in launching products, I think a team approach makes a lot of sense in what we're doing in terms of increasing our head count both with sales personnel, practice developmen</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t personnel and clinical apps people is really surrounding the customers, specifically from a practice development point of view, how do they become a lens-based refractive surgery practice? How does it get reduced into the fabric of that practice?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And we</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">'re just coming off of a practice development seminar recently held in Austin, Texas, which was well attended by practices where they learn the tools and the </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we have available to certainly drive towards that end goal. But I think, again, surroundi</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng the customer with this team approach where clinically marketing-wise and sales-wise with common management, so decision-making as close to the customer is certainly a recipe that has proven successful, and we're poised for a strong year in the U.S.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Margaret. Operator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Absolutely. Our next question comes from the line of Bill </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Plovanic</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Canaccord.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Unidentified </font><font style="font-weight:bold;">Analyst </font><font style="font-weight:bold;font-style:italic;"> -</font><font style="font-weight:bold;font-style:italic;"> </font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m, Patrick, it's [John] on for Bill. Can I? Just a follow-up on the Margaret's question, could you just talk about the hiring cadence of the clinical and sales reps for 2023? And beyond the cadence, typically how long these reps take to become productive?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. Thank you for the question, John. Again, I think at an overarching number, we're going to increa</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se our field infrastructure by 50%. We've already hired 2 or 3 people in Q1, and we'll continue to look to hire people throughout the first half of this year. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> they are productive in the back half of the year. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I would say we're looking at very experie</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nced people, people that understand missionary type selling as we bring them into the organization or working in practices that had a cataract refractive mindset, if you will. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I think the start-up is probably a quarter, but we hope to increase our infra</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">structure in the first half, so they are effective in the back half.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Unidentified </font><font style="font-weight:bold;">Analyst </font><font style="font-weight:bold;font-style:italic;"> -</font><font style="font-weight:bold;font-style:italic;"> </font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. And just a follow-up, too, for me. As you [past] the 50 days, I'd be </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">really curious what you've learned in terms of reality versus your expectations going in? And perhaps a little bit on the strategy of more KOL engagement?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinz</font><font style="font-weight:bold;">i </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. No, I appreciate it. And as said, I -- the first 50 days, there's been no surprises, which is the good thing. As I've thought about our strategy, our people, our business in general, I'm extremely e</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ncouraged. And if anything, just bringing maybe more focus to increasing the infrastructure in the U.S. and continuing to support the infrastructure we have outside the United States, and I think there's growth potential in both those segments of our busin</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ess. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> nothing dramatically changed. I think just reinforcing what STAAR has said historically and maybe bringing just some added direction and focus to making sure we're putting our best foot forward in a market which today is white space, I mean, the U.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S. And we're excited about what we're prepared to do here.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, John. O</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next question comes from the line of Anthony </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Petrone</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Mizuho.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Anthony Charles </font><font style="font-weight:bold;">Petrone</font><font style="font-weight:bold;"> </font><font style="font-weight:bold;font-style:italic;">Mizuho Securities USA LLC, Research Division - MD &amp; Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congrats again, Tom, on the first 50 days here. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I have one on China, one on </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the U.S. On China, maybe just a little bit of the rescheduling of procedures that have been pushed out due to COVID, how substantial was that in 4Q? Is that still occurring here in 1Q? And sort of what is the timing to recapture those surgeries that, if yo</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u will, got put back into your backlog? And then I'll follow up with one on U.S.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthony, it's Patrick. I'll take that si</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nce it was on my watch before Tom got here. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as we talked about, there was about $5 million in Q4 that we took out of our Q4 number in '22. And </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as Tom said, we're feeling really good about it. We always talked about </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it,</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> this was transitory in nature. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">They weren't going out and getting any refractive procedure, right, because everything was either locked down or getting relieved and people were unfortunately getting affected.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So as Tom said, we're back on track. The end market numbers in China are very</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, very encouraging for us. And so that led to obviously the reconfirmation of guidance once again and the comments that we made in our prepared comments.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Anthony Charles </font><font style="font-weight:bold;">Petrone</font><font style="font-weight:bold;"> </font><font style="font-weight:bold;font-style:italic;">Mizuho Securities USA LLC, Research Division - MD &amp; Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. And a follow-up on the U.S. side would be around the FDA proposals for patient disclaimers for </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LASIK that the co</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mment period there came to a conclusion in the end of November last year, we should see, I guess, a final draft guidance at some point this year. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a couple of questions here. One, what would be your expectation for timing for a final draft document to be</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> published for the LASIK patient disclosure requirements? And then two, should we expect ICL to show up as an alternative to LASIK in the final documentation?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. F</font><font style="font-weight:bold;">rinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks, Anthony. Let me try to answer that. If I could predict what the FDA is going to do, I'd probably be doing something different than what I am doing. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I can't really comment on the timing of </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their decision. But as I've said before, it's a practice of medicine issue I think at STAAR, we don't want to get in the middle of. But as it relates to us, I mean, let me remind you, less than a year ago, FDA did a careful review of EVO's clinical trial d</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ata [to have it] safe and effective and granted us approval. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I don't think we're impacted by this, but the timing around when it might come out and the tailwind that potentially it could cause for us, I think is an unknown at this point in time.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Anthony. Operator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next question comes from the line of Zach Weiner with Jefferies.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Zachary Ross Weiner </font><font style="font-weight:bold;font-style:italic;">Jefferies LLC, Research D</font><font style="font-weight:bold;font-style:italic;">ivision - Equity Associate</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Just one on diopter correction average throughout the year. Can you talk about the average lens correction that you saw in China in 4Q and how that trended throughout the year?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes, Zach. We haven't really given those metrics. Occasionally, we'll talk about the majority of the lenses being below minus 10 now, and that's still the case. But I think </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overall, as we're in a market, we tend to see the migration down the diopter curve. And clearly, that's an area of focus for the company, not just in China but globally. And certainly, I know Tom has talked about that specifically in the U.S., especially a</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s we look to go forward.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Zachary Ross Weiner </font><font style="font-weight:bold;font-style:italic;">Jefferies LLC, Research Division - Equity Associate</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Got it. That's helpful. And then just on ASP in China. How has that trend</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed throughout the year?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. We're good on ASP. I think maybe I'll answer this in terms of the gross margin. We saw a lit</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tle bit of a dip in our gross margin for Q4, and I want to make sure everyone </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">understand</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that, that was more of a byproduct of some one-timers as we close out the year. As you heard in our prepared comments, our gross margin for 2023 is going to hit that -</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">- I guess it's maybe that magical 80% plus number in terms of gross margin as we go forward. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> there should be 0 concern about ASPs, the nature of our contracts, the nature of how we set stuff up. We don't get variation in pricing.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And there should be no</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> concern about gross margins in the fourth quarter. As I said, that's sort of some one-timers as we close out the year. It was also one of our lower quarters in terms of overall revenue. And of course, you've got to absorb some of those fixed overhead cost</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s, which did impact it. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we're in good shape overall when it comes to ASP and gross margins as we move through this year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Inv</font><font style="font-weight:bold;font-style:italic;">estor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Zach. Operator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next question comes from the line of David Saxon with Needham.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">David Joshua Saxon </font><font style="font-weight:bold;font-style:italic;">Needham &amp; Company, LLC, Research Division - Senior Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congrats, Tom, on your first earnings call. Maybe I'll start with Pat. I just wanted to see if yo</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u could talk about how much of the investments tied to the U.S. launch are expected to continue into '24? And how we should think about the rate of margin expansion over kind of the next 24 months or so as the U.S. launch range? It seems like guidance is i</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mplying some contraction in the first half and then kind of switches to expansion in the back half. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are there any reasons why that margin improvement should continue into '24? And if so, I mean, should we think of the kind of 15% that's implied in the b</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ack half as a good jumping off point for our '24 estimates?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. I think we haven't obviously given 2024. We're getting o</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur arms around 2023. At some point, we have talked about doing an Analyst Day, Investor Day, where we would provide long-term metrics. I think for now, you're on the right track. Clearly, this is a year, as Tom outlined, where we want to make some strong i</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nvestments specifically in the U.S. market, and as we move throughout this year, then we'll see how that goes. But we're clearly one of the only companies out there that's growing at the rate that we're growing and still throwing off cash and still have a </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">very nice operating margin profile, et cetera. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I think directionally, you're okay, but I don't want to back us into a corner as of yet, but it's a very, very elegant and leverageable business model at the end of the day.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">David Joshua Saxon </font><font style="font-weight:bold;font-style:italic;">Needham &amp; Company, LLC, Research Division - Senior Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Got it. That's helpful. And then on the U.S. launch, can you just talk about the growth? And is that coming from new d</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">octors or existing doctors increasing the volumes? And then, I guess, for new doctors, how long does it typically take for them to fully incorporate ICLs into their practice and kind of reach a steady state in terms of volumes?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. Thank you, David. Let me attempt to answer your question because I think it's a little bit of a combination of both. But as I</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> said in our prepared remarks, our focus is certainly, we'll continue to certify doctors as they come on board. But I think it's equally important for us to go deep with the customers we currently have. And that's why we're increasing our infrastructure an</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d surrounding the customers we </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently have as they continue to reduce EVO into the fabric of their practice and make that transition from being more laser vision focus to maybe lens-based focus. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a little bit of both. But clearly, I think as we go dee</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">per with the customers we currently have and really drive adoption of our procedure business will take care of itself.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - VP of Investor</font><font style="font-weight:bold;font-style:italic;">, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, David. Operator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next question comes from the line of Thomas Stephan with Stifel.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas M. Stephan </font><font style="font-weight:bold;font-style:italic;">Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. First one on the U.S., sort of a modeling question, but Patrick, maybe this is f</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or you. Can you just help us a bit with how we should be thinking about the U.S. ICL revenue cadence in 2023? Appreciate the 1Q figure of I think you said $5 million. But can you just help us with the key assumptions or expectations back in your view on th</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e ramp for 2023? And then as a tack on, I'll go for it here. But just on 2024, any guardrails you could provide just on the U.S. ICL sales ramp?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR</font><font style="font-weight:bold;font-style:italic;"> Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I'll stick with 2023, and we're probably going to punt on 2024. But in terms of the cadence, it's consistent to what we said before, right? We said this is going to take about 18-month journey for the surgeons to get all up and r</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unning. That's really going to happen as we move into Q4 of this year. We talked about approximately $5 million in Q1. We would expect to see some sequential growth as we move throughout the year with really a back-end loaded number as we approach, honestl</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y, looking to approximately double our U.S. business from 2022 to 2023. We did provide that supplement out there. And if you look at it, we did approximately $15 million in revenue in 2022 and the doubling is consistent to some of the comments we've made p</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reviously.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas M. Stephan </font><font style="font-weight:bold;font-style:italic;">Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Got it. That's helpful. And then if I can pivot to China a bit. I mea</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n it sounds like it's coming back very strong. And over the past 2 years to 3 years, it's performed extremely well as well. So how should we be thinking about ICL demand just as the economy reopens, people can travel, they can spend on a greater, I guess, </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a variety of things besides self-improvement. We saw this a bit with clear aligners, maybe as an example. I guess what I'm trying to ask is, what gives you the confidence there hasn't been sort of a pull forward in demand that we've heard about and then ma</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ybe we won't see an air pocket as wallet share competition in China picks up?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. No, I'll take a cra</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ck at that, Tom. And certainly, Patrick can add his comments as well. But as I've said earlier, our local team is extremely confident, our in-country or end user demand is starting to pick up, which tells us the refractive procedures are approaching back t</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o normal status, which continues to bolster our confidence in our ability for the China team to meet their goals for this year. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we're very </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confident and very excited about what China is going to be as part of our overall business this year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. And I think it's a good reminder. We've talked about this as well in the past that in our Chinese market, we've got 65-ish STAAR</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employees on the ground that Tom referred to. And we have a very rigorous forecasting of cadence around globally. But specifically in China, we know exactly what's being sold in the end market, as Tom said. And </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we -- that gives us further confidence in</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> terms of reorders and everything else when it comes to China and where we'll end up not only this quarter as we move throughout the year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Brian Moore </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Comp</font><font style="font-weight:bold;font-style:italic;">any - VP of Investor, Media Relations &amp; Corporate Development</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks, Tom. Operator, next question.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our next question comes from the line of Ryan Zimmerman with </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BTIG.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Ryan Benjamin Zimmerman </font><font style="font-weight:bold;font-style:italic;">BTIG, LLC, Research Division - MD &amp; Medical Technology Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glad to get on the call here and ask a few. I guess I want to ask a </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">couple, if I could. Number one, as you think about China and what is contractually obligated with your end market customers for the year? And what dictates whether those contracts are maintained? I mean if COVID were to spike again, what kind of impact wou</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ld you have? Because as I look at the first quarter implied unit growth, it's about 6% at the midpoint of the guidance. And </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I'm trying to figure out is, is there going to be kind of fits and starts here with inventory levels just given that slowdown in </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the first quarter. I appreciate your comments on kind of both of those topics, guys.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I'll come back to the guidan</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ce, right, and the $340 million and the composition of it, Ryan. I think Tom made a comment that we have over 1,200 individual physicians out there in China right now. And </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on top of that, I know that there was some work done on </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocFinders</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and things of </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that nature. There's not always a one-to-one ratio between accounts and physicians. And as I said in my question before, we've got very good visibility in the end markets. We know exactly what's happening by procedure, by account. And </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the question aroun</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d -- and I think you used the word pockets or maybe a pause or something like that, we're just not seeing it. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I'll just come back to you, we feel good about the guidance we gave. We reconfirmed it today, and China is doing very well as part of our prepa</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red comments.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Ryan Benjamin Zimmerman </font><font style="font-weight:bold;font-style:italic;">BTIG, LLC, Research Division - MD &amp; Medical Technology Analyst</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. And then I'm going to try and just ask 2 more. Hopefully, Brian</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will not cut me off. I apologize, Brian. But number one, as you work through the IOL business, that separate business, I mean, you've had negative price pressure as a result of that through the past few years. Now that that's going away, how do you -- </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> commented earlier on price, Patrick, but do you anticipate needing to use price as a lever in the U.S. launch? And maybe this is more geared towards Tom, will you use promotions with price in </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the U.S. launch to spur demand?</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And then I'll sneak in my last</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> question here. R&amp;D is going up to $11 million a quarter, as you said, Patrick, what are you guys spending on because you're not in a clinical trial. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> I'm curious kind of where that R&amp;D is going this year. Obviously, we know where the sales and marketing</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> spend is going, but I'm curious if you could comment on that as well? Sorry, Brian, I know I'm one over.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chair</font><font style="font-weight:bold;font-style:italic;">man</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. Ryan, let me try to address your price issue as it relates to the U.S. I think the old adage holds true even in this case, if you sell on price, you can lose on price. And price is a non-factor in terms of our growth strategy in the U.S.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Patrick F. Williams </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - CFO</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And then on the R&amp;D side, Ryan, it does include other stuff besides just sort of what people think of traditional R&amp;D. We've got c</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">linical in there. We're still doing the post follow-up on the original supplement of the PMA, right? It's a 3-year follow-up. We did have a second part of that study, we had to do related to IOP. But we've also got quality in there and other things. </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">just want to make sure that we're supporting the organization, as Tom talked about, one of the big things that's clinical, and we want to make sure we have a strong podium presence, et cetera. And I -- we feel good about that number, and we'll see how it t</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rends as we move throughout the year.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That concludes the Q&amp;A session. I would like to turn the call back over to Tom Frinzi.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Thomas G. Frinzi </font><font style="font-weight:bold;font-style:italic;">STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="font-weight:bold;font-style:italic;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That concludes our call. I want to thank everyone for joining us today. Please reach out to Investor Relations with any questions you may </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have. Thank you.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font><font style="font-weight:bold;">Operator</font><font style="font-weight:bold;"></font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That concludes today's conference call. Thank you for your participation. You have a wonderful day.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;">&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;&#9472;</font><font style="color:#001EFF;"></font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.66%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:63.77%;"></td>
<td style="width:36.23%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:6pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>staa-20230221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-02-22T17:22:12.1080188+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : deb5d3bb718046e4a3e35304f41869b7 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:staa="http://www.staar.com/20230221" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.staar.com/20230221" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.staar.com/20230221/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>staa-20230221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-02-22T17:22:12.1080188+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : deb5d3bb718046e4a3e35304f41869b7 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>staa-20230221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2023-02-22T17:22:12.1080188+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : deb5d3bb718046e4a3e35304f41869b7 -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.staar.com/20230221/role/TemplateLink" xlink:href="staa-20230221.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="staa-20230221.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140558301586016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 21,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR Surgical Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>staa-8k_20230221_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20230221.xsd" xlink:type="simple"/>
    <context id="C_0000718937_20230221_20230221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000718937_20230221_20230221" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000718937_20230221_20230221" id="F_000004">0000718937</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000718937_20230221_20230221" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000718937_20230221_20230221" id="F_000002">2023-02-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000718937_20230221_20230221" id="F_000003">STAAR Surgical Co</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000718937_20230221_20230221" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000718937_20230221_20230221" id="F_000006">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000718937_20230221_20230221" id="F_000008">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000718937_20230221_20230221" id="F_000009">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000718937_20230221_20230221" id="F_000010">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000718937_20230221_20230221" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000718937_20230221_20230221" id="F_000012">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000718937_20230221_20230221" id="F_000013">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000718937_20230221_20230221" id="F_000014">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000718937_20230221_20230221" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000718937_20230221_20230221" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000718937_20230221_20230221" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000718937_20230221_20230221" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000718937_20230221_20230221" id="F_000019">Common</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000718937_20230221_20230221" id="F_000020">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000718937_20230221_20230221" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000718937_20230221_20230221" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:XC-I6:,U+P(MO$\_NWL^)E=!CNEG\T:P++7+)5FZ*VMW5PWFR9>0\;-I=J
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M?1<Q>XR!2W:K<1U $9?6']#F_9%X[,YPQN=J5]TY:;D'_@P,UQI@+(57-H6
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( ,J@5E:*FN$)[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,J@5E:97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ RJ!6
M5A?D)3%-!   BQ   !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( ,J@5E:?H!OPL0(  .(,   -
M      "  9 ,  !X;"]S='EL97,N>&UL4$L! A0#%     @ RJ!65I>*NQS
M    $P(   L              ( !; \  %]R96QS+RYR96QS4$L! A0#%
M  @ RJ!65CJJHN=  0  / (   \              ( !51   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ,J@5E8D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ,J@5E9ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="staa-8k_20230221.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="staa-8k_20230221.htm">staa-8k_20230221.htm</File>
    <File>staa-20230221.xsd</File>
    <File>staa-20230221_lab.xml</File>
    <File>staa-20230221_pre.xml</File>
    <File>staa-ex991_24.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "staa-8k_20230221.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "staa-8k_20230221.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20230221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20230221_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20230221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20230221",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20230221.htm",
      "contextRef": "C_0000718937_20230221_20230221",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20230221.htm",
      "contextRef": "C_0000718937_20230221_20230221",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001564590-23-002247-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-23-002247-xbrl.zip
M4$L#!!0    ( ,J@5E;-&R:OJP0  /85   1    <W1A82TR,#(S,#(R,2YX
M<V2]6-]OVS80?A^P_X'U4XM5/QTGL9&DR.8&".!VA9,.?2MHZNP0I2F-I!+[
MOR])F;+DR*ZL9/-+*-[Q[N,=O^,Q%Q]62X8>04B:\LM>Y(<]!)RD">6+RUXN
M/2P)I;T/5[__=O'&\]#XYO8SNB:*/L*82L)2F0MX>_?I'?KVYW2"[L@#+#$:
MIR1? E?(0P]*9:,@>'IZ\I,YY3)EN=*NI$_298 \SQG^2P V C3&"I#]C5 <
MQGTOC+TXOH_.1G$\BF(_"L_#Z/S\CS <A6'%P#_%'E#E-T(#/_0C_VS0KRA^
MP>0'7@"Z'5<4$Y@-DOYL=A:=AR>G<(+[T!_TPY/Y271^.IR=59&FV5K0Q8-"
M;\D["U'OEW-@#-;HAG+,"<4,W;F=OD>WG/CHFC$T-<LDFH($\0B)O[&ZDLE(
M%I'3V>!R)!7&E[U*Z,R$L"$S_L(XCGH;U01HJ;F:">9+(/XB?0RTP"C'3E'G
M4JTSD*7V',N9GXI%X"0U=:DRT6S82.JJ0NTS78KJ"RC98YJ2FJ(1)JJN:\S&
M83@("F$9!R5V0)BXE2NT.#!B8S[TPLC;1E!C; 1>0P(\7\9-0.(P@)4"+NF,
M@6?40-B#++W8D*D,_@+CK#'V1E#SQ3$ELCE 5O0L1+1YSSI*_4!33ND3"4Z?
MI#E78MUL?B.L.6"4_SA@WXAG6);V5\_TG_I6.QH.AX&5EE!R(72MV8=E(ZVG
M844>FM6-9*.*E1)TEBNX2<5R#'.<,YWAG/^;8T;G%!)=XAB8^E13J(@5%@M0
MG_$29(8)M*2BIG'3QG68HN#;ITE1&WN:\ A9RM-EE@J%"N9/4F*/S8%0FR_/
MY=,S4UX4>_W(U\9ZB#>BW7<8@A?"<&GO!&-[9CK#</0W_@?[/#?7BW8^Y7.G
MAZG> L2O:D5[9'M9ZSX\\W$04C/GNT*HDK7\.@)$G>P=4;@KSPS:^]Y>E!U/
M1L/=8K]E*T8TWDP= U 603MJ'X)*\>S&2"9$@ 41*0-]MQ'U<94QS+%*[4D,
MAZ9"1*=M*\2P9LN#K;$;_?T2C-8HAX7N,9-.P*H&7@&(>@F(HVK9GC:B&+8_
M*=4&I*-SU^2907O'V];P2+?/6KH F)*V,SWDO*$3?#W')H&'@U[KH*WZJX.P
M):H]B&H;WS7S[N5@1T?D?OOBZ+K]:I]=A& STRX ]3;]54$<<1:<]G\!XXC3
ML/->K,# G*?*^K9S;C;+*)^GFRD]:?J_D=G)O3:#J.Z:[V&I:[R"B7T>&-'7
MZ>TOVNZB#-97'O=D*1$Y3 G,*:<6?VA^R*O^*\.Y0L;71;"[8M=8+B'YFU_9
M<2;TDY\7H:FLWJ@<6DDP(SGKL'"+;/^ZS:Q+Q4Z&7)RF,$?VX3;:7,N'GW=!
M)M(,A*+ZA%1>A]; @X#Y9<_DTG-I_,[PS-=Y<RK/'-239Y.NEP";;.&YM8HJ
MLWABQ#9+\CW"K#1M3JWVKLG"RK?'_[Y=?12.W>[NZ6G>]9>*UM&;+]G8DGL*
MKU*>+M<%0$<2]_>:)Q^YAK6^U;P72PNI9XD^U>K?6ZD?(F?4P,YRJ*VAPARJ
MV#N.KYU9UYWHW?EZ$>Q6V<U,M1H74\4%<?434$L#!!0    ( ,J@5E;V;X5[
M( <   M)   5    <W1A82TR,#(S,#(R,5]L86(N>&ULS5Q;<^(V&'WO3/^#
M2E]VIVO,)=DDS&9W4I)TF&:33,BV.^UT=H0M0+-"8B23P+^O9)N+03:^B$5Y
M"3C2.9_/.9\E$^##I_F$@!?$!6;TLM:L-VH 48_YF(XN:S/A0.%A7 ,B@-2'
MA%%T65L@4?OT\>>?/OSB..#ZMG</KKP OZ!K+#S"Q(RC-_W/;\'7WY_NP!VF
MWP=0('#-O-D$T0 X8!P$TX[KOKZ^UOTAIH*162#91=UC$Q<XSA*ZRQ%4?P#7
M,$ @_.F 5J/5=AHMI]5Z;IYU6JU.LU5O-LX;S?/SWQJ-3J.Q ?!7=%I@XZ<#
M3NN->K-^=MK>&/@(O>]PA$#O>F.@CP:G?GLP.&N>-T[>HQ/81NW3=N-D>-(\
M?W\Q.-NLE$T7'(_& 7CCO0U+E.=+*2($+< MII!Z&!+07Y[I.]"C7AU<$0*>
MU#0!GI! _ 7Y]1B52-TZ9"F>](B*\.EE;4.]^8"3.N,CM]5HM-WEZ%H\?+XS
M_K4=CFY>7%RXX5]70P76#92P3??KY[N^-T83Z$BK9 H\12!P1X0'[Y@7>I2C
M+I Z0CUSEL,<=<AIMIQVLSX7?DVJ 4"D!V<$/:$A4+^_//52.2]<-<*E:"2#
MX]_! 2*RYA!BS-%0/X]PGIBFZKA0=33?JSI^U:$%BZGL!X$G4R)5<2N7>H\"
ML]5N YHN^!%QS/P;:EAD/>QABN\'D!M6/0W8] D\R^L;,EOZ+J3QHED B>&B
M=R -%ETB&\%NG56#,(1B$-+()7D$X32B(@K4A7,LKM$0SDBP6Z:0D\,:=Q#D
M,M5R$0F$.J+@A*,.A05K(--K#JM0"WT\4F%EK =1Y='JLX&,Y@&B/HHO^"ML
MYJ6?DD!>?<1>7!_AZ&SD@_4YR"??;FB @T57[CLX)#T)/_\3+9*\1*U@C"\/
MAB=S6<N8["8+5./5,BH?J2T3HLZ7?EZP;V2PE0F.!)OQ<(W-K66P[MF/$0V(
M>4!(!"33!W==T&[]5]Q+5 &YMRQ /MQ30SS"]9C<&TP#AVPF?<C9)%/-F);M
M5<DUF8LNDUO>JX&0-%Z0-P];D\KE( %BQO](\(\A,OAWB?W?\2W7J\Q2A3!J
M\?*&XUF>7EZ'DW/*&;R)8;Z_5[=1"O[X#FM%9FE"V"(H*:1EM1A>209?L=P2
M.,J;PZU)Y71+@)A/X@H>*/SC1U$O-$O5PAI123$]S5P55W=8ZK65HI?'K<G5
MVCH!=L +9L0#)%'X>M+Q YMM!=NKDG6R;U]6<RMN8H__A$98[25H< \GN1.M
MGUMEAY_$.M@&?TT#%,_QTYSI MNGD&V*D_)B'_=>,%EX@=M $SUX,T%\A.GH
M#\Y>@W&73::0%KS;3H&HD@\MY,$:<\D&(CH0\]G2H-D6L9RZ66H'J>:$B1:X
MQ03=SR8#Q(OE?G->%777. =+N*( $8<MJ=:HSK)4L4EA4EQ<$T'M48_Q*>/A
M?^_Z@=R?==E,KA:++O,+;I_V0%41.Q/Z8 E/L+X#(2]@',3<0)';$OU\/K*"
MHEKN&4FW*W8KGU4F&ND9SGN^W&?A(8[^%5[F\I\*4L6(%-"#M8WD TE"RY:)
M?5:QW.I9:PNIZHB)EKCR?5F[B'_=88J:Q=I!"U!%<PW@P=H@)GFW?*#> X7
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M+&W@O938FQ2H'9 ,'BF"T-<E]II]HQ=UHS@?@$^"52.8O4IC18*EH&D@;*W
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M<Q652([UPNPKH3+(Y65&LO*JJ]0L?[KMO!([(Z-SP[Q-21ES'@4V4I_,]"X
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M)YX7/F%RDLD2J9R67L5"JKE6IR3*4-<.*97"&BK)S*)-!1<"BVIDDY0@.#\
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M/HJ)$I\  LW1J. TS?.4_B')FC![;09;I(7XP@&*$)7-D;]D9=$3,T6!:"M
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MD.4M'[0IX<0@,/Q:+Z*W=JZR=8H@(9*-R_P)%K>9R(6CXU?QEX]9+;QX>)C
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ML>LLX\[8+J_2-Y<(")<JSW76+K_@>-0O>[*N'L8+R[12+</M?M]SI2(]KM%
ML"^_;//OI49&= M?MBVE*IHT/^Y3ZY(T+ZS^$'0[(1(W<L4*RA"I[ZE5Z/?C
M@"[E&3PNA=S0&2U*6:4=V08R!= MP:WZZNHEMD9^!O0M5C%"U(4="$3R.[A'
M*ID %FD:]40:1]1YGDIQ;:AM&?EJ6J@TW*=!(;]6FF"C)?7J_FVO;*!72T4=
MW0G=AGF@F()9/V$-+J .(*LXS&?H1T+CS#NR#>B_S95L-]KATE_ZRQ=3W'IG
MRE=I7V'@"("EGYLS@6B5'D3LBA@)@$)'YL(@HB6R%QUZB%/1N!:#W0U<_"85
MK Z']DR+AI4KLK]W6 U@+6M7_NG4O%P7>+N&FE$5) )3)'8">;[D*]&D98],
M@R-QWB,#BS[1<P@YMO8=!HHF"6?GP+2PI"'1&W/Z1ZIYS6G>9R!4R>NA#\J<
M:_'0B6H*-Y@N6G49'=D&Q>#2VG<&8_"=,2=QEQ%R.88ME(Z R,\J8,N]Q9DP
MDE^JL0WBK%/<+TN_I^.:ZE' *&>]^_#NG-9KZ36?\I2TAX%\A6IR<;J(WI!-
MC/C!I#QWIDK45(XUD7OC/LQKVE^'60X-Q6V=+]@EC4.PWYV>ZL_+O"NG >O%
M%>28&W1B=!I#NI>-3S53WX(472"$SY!J@[IE71D/9".'/"?3J21+HW<_]9=O
M^-)7S'1&7^&*F=?6.=[%=Q+%15>8;GPJ-?/H-7)BY^>:,WKO(V2Y2I)HQA:N
MLV.#,N&+<R!DV&F$K% #62]8^]CO2JLY[.-&(?%RK1JX&I-A3+H0B40.O= X
M:F3M.C%F2L&_\WXO#*K./9I]A;H-KGX!3H6><(;PF6XR-DL&Y/).D*!?=066
MW[I_<IUH'4#Z?68T:WA$Z25Z<[I&&EXE<#5(:FQ2]*GS'CB1A[SH2'76NG+9
MTU.K4M^T,WBQ.K(,W?'$BK^5U>^^B*@O(KJY143?]45$?1'1M2HB\EH#F[""
M#O0^-E6(P+ %+>*O';82:SQ78BY#9/IV+B&LT'=G^0#[H1.&3G^Y 29F#T/Y
M(;;D/G?47 %08/1<,JH@@#@D?7<=PU&\E6*N>:A!]B"S=]"9$."9NM0!?E"<
MANAS]N#^T)2SZ/+LD2^LH>MYGMJE!FYAYG&-:N_O!#HDF8&Z*!@R7%;-HUL*
MLASR'"S=PK:0CI6@"Z'/F\LY=$"9T]2.$6 7*W<=LY'E# >/3S.[@*<W1CWA
M0J(34H):$EGY1==<LNK@'07%$@:S#+ C2UMVR J+AD,'9\DN<>P6>@3J-1.X
M*P,.F3>%9NNN9"6%F]UR8"'2*1VP<_WC7(0*-.J 3.$L8A=(3D^O!*F3#[%K
M6?@'F2'?N@+37[[IRS4H/_WH9VVJ6_WVRD]+YZ[N*T_[2W_YC/SOAE>>OET2
M=_^GF<\U@HV2RM&1.3P].?RIYV/]Y1N^?$(^Q@?]J<Y^HW/3/O$?K0WA>%X"
M1?WJF=/!H)E!Z3O1\2RCL4^7-P6?^J=4);[ P_E@X!>)7->KA'/:5#31BR;S
M[3!T I O.S*5V-8Y6CY(\BA2(D?1:RF?H+O852/9>$U3N;;-#A]:&5JK"3"G
M':=FBH1<$2I<-=IX?UI 5#YB#[M=RC;Y@40UP(Q&LJ!FAT<ULV73OTT2&N;*
M9$C5T,F/KC48IG!P].OALVC!G3QL5.9(+553^IE++_08U6:>TY-0C]*1;4@3
M7F9XZ7ZDPRIHL4@L"94:3;\Z[PCQ_<WJS%2N;,8EP<H^/;CC[YN;1-J*N7H,
MWZNO=[Y=4(S6SD_U9=:H,$.6<>ER4=OQ-4]7$U.5KO,+[5$I#(%/ =H]9J1-
M+KF+1UI*8K$T3Y*2G=0N$KO@E,Z.+,0YD@,W4TT=^E(2<EQ.E&UZ)P(F3V@-
M![>RN8EIY:;ULNS5NO[R#5_ZV.&7/^H<.^S(6+J3YG<H<.QSU\O6 <Z*8M"1
M,<:^)'L0RDUO[^YMA;)4_R'J(:S#OV48T@$[-YJ.>X@U<LVI\M+*UX9(6)1+
MB[8'.UM;)'P3LF024F2C?+8L#0FZK-T?+M1;2+N^S"YZ'6HC?<$LLKDH 4BQ
M/I0PL> 5BUI$ZBT7"2]L<8IF:0P/U)'Q/[/Q"TXJ*#LR($?M7*)%B]J14?%V
M9@JM$5"82-M*U@?"MI+'2 >.;AY6=HC=1;-!:,O5 N5;*N:<=U&7F[,FQXDM
M']]H8KYL-](0J(8F0X,S&C@/!!X(EPM^+N>@Y/*U39D* G? >?'+)FM^@+_<
M$/L3OCGB3PL<]H531CHRL@2I$ZJ5+ 3+N@;,.89,W"9QE76,=.7*%:.<36[N
M>3_7DK+ E:G"OB0KGFTVD'>I.;\%9;4=F73'- M>J17U@E%S2>).M$[EO+8:
MLSE_!".H<VN6=RAFX407KN5%HS*;H+4F]C6DN$J#7N8 OL:WG>;*W6DZLBQ(
MQ_*F<F\$]Y=O^-+'-KIL+DOOS0 J 5]H X!%C+8%BG :[7"7D5'T/S;7W"YR
M$'':4$?F(DTJ(+#CFONTV<E$?)C8,GJM&ZYDN&;GPQYLFK@L0Y94AT<O0]7$
MP#ENT0(-[M#F<PE(2%-HH ^H),KT5+G"3#1P(=%4EMQ0#$HR_5&GE3>65E[(
MN<H3O1"0"Q34!B-*.I5+C_H%9"-@+1*6M-" .K('R\[$6+S\U:%*%P8G[\>@
MP9H%\*Q;1+J=C)(<>YMIG;A# #51-I'WCIMRKS2QEU:T$M!:1:[EECQ3K20W
M&W 5G @]$#IU:BJ,D+F59#8.'<C+6F&!OAZSK\>\>?68C_IZS$^PCGT]YA<-
MC[88OF0<U!ZWH<M /%]A&"V%$DBO&1TQY]M+U25*\Q?6$((_2P SW[*R_ZRI
MIJUS[/+M[>TF".%CXT%GA-NRI4]PW@DR5O =0N""#,8E5TUC8&B*]!NHJ@8/
MC5.3L8%!3U%I[V7:F*,1UP6@.T/:@900L79\;N=:D!]'8X?XV52O^3NU W)7
MP7%,]W9ERH(HYV<DFFI[&1RTJZ#5^T"7=>DEK@3RQ^C8%H4WTT)8!H_A  SI
MLKUWJK]\PY>;@B#VT>^Z*=!C\ T.(L FSC5[KI!ZFR1PO$CFFK.KR[)F4YX4
MX )59%*8VG3W<$$D?(!R9I60C1#-Z)_TNX)N!3*VV/_(A%6E)-.R)H"81.-B
M8.:LLBA%4IS_6%QM?B@D^6E>M%IQ98L50'L,V$&CEQ7<3=-EV^G0D87_ CR[
M%PO]Y2OS]3[U[D.-/E<DX;5RB*R!8] &[E;BN2:+TSHAQL@I_V553R8!BYCC
M#1[OEPTJA[PLK!E^\T(EG %&2^C>XN% D"02=V1!O%4GG+O@0#?L/C(Z250D
MSE+146[A];=I:A=#LCG=\MG"3 UFV&[O(!G];U[MA_XEAX*-LCOD3AGA*:%3
MA(,"*1%?3T+ 7&(959V(6323"I?$.J'(?QT>O9%0B:3?J+2TO+QD K?2;EP-
MC'6U&TA9Z@W830@?'1D*GRY?G#0'3BM'ICQ\-LB3Z,TZ!%*FPZG*S.]*.O4Y
M,)<VZLY C$DAS;&9^L0U%[/RS@W?X&?#RQO$&L& IQ.1F'K.<3-IZH-*(DWJ
MD?+ 0,/AYO02Y2-[H9\0'%!:<[@,B24=V89" PV_1S?I+_WE\^MPU[.Z'[T_
M4 C)JI)@/O_"VLX^<;2RY'Z?AZ[-EF0ODB5;%ZT254['DUX:EOFVN"9ZQG(]
M+OWZ='KIKX-C\ ;X]];8()>A*L#Q-T7V%;"2!'\.NBA*S7\C\XJ#>*4D$X^B
M-ZE6)3*-53R3(A\;D*5:D%*<A8-E]>%!"?3-U;(K*OR,DZ89'XI[4G=D6#VW
MZB_7FU/?##41W$Y:X$YTP<"APBX#PV#^*$$1=!KAI$=6)O_A0"G($%]8U,--
MZC0"[^S(3'L.\_6.4"<&VMW+AW"A/J.WS^B]>1F]VUM]2F^?TOMAXKQGA#TC
MO'F,</O:,\(.,8A^5M=G5G^6YL\[)#'<!Y=.Z$\,]_M[8YLLL1?W9M4\I7_\
M?U!+ 0(4 Q0    ( ,J@5E;-&R:OJP0  /85   1              "  0
M  !S=&%A+3(P,C,P,C(Q+GAS9%!+ 0(4 Q0    ( ,J@5E;V;X5[( <   M)
M   5              "  =H$  !S=&%A+3(P,C,P,C(Q7VQA8BYX;6Q02P$"
M% ,4    " #*H%96F.2ZM_4$  !)*P  %0              @ $M#   <W1A
M82TR,#(S,#(R,5]P<F4N>&UL4$L! A0#%     @ RJ!65E=P+9A=%@  OL\
M !0              ( !51$  '-T86$M.&M?,C R,S R,C$N:'1M4$L! A0#
M%     @ RJ!65D2<0^8710  F4\" !$              ( !Y"<  '-T86$M
B97@Y.3%?,C0N:'1M4$L%!@     %  4 1@$  "IM      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
